BioNTech (BNTX)
(Delayed Data from NSDQ)
$87.25 USD
+2.40 (2.83%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $87.26 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BNTX 87.25 +2.40(2.83%)
Will BNTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BNTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BNTX
Pfizer (PFE) Beats on Q2 Earnings & Sales, Raises 2024 View
Pfizer (PFE) Q2 Earnings Coming Up: What Should Investors Do?
BNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?
Pfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Other News for BNTX
J.P. Morgan Sticks to Their Sell Rating for BioNTech SE (BNTX)
BioNTech price target lowered by $3 at JPMorgan, here's why
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
Maravai cut at Morgan Stanley; Pfizer/BioNTech headwinds cited
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows